Oscar Health Inc vs Thomson Reuters Corp — how do they compare? Oscar Health Inc trades at $28.79 (market cap $9.28B), while Thomson Reuters Corp trades at $87.84 (market cap $39.68B). The key difference: Thomson Reuters Corp is far larger — about 4.3× Oscar Health Inc's market cap, and Thomson Reuters Corp pays a 2.89% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| OSCR | TRI | |
|---|---|---|
Market Cap | $9.28B | $39.68B |
Sector | Health | Industrials |
52-Week High | $32.18 | $205.54 |
52-Week Low | $10.85 | $76.55 |
Enterprise Value | $4.90B | $41.64B |
Dividend Yield | — | 2.89% |
Signals from Pluang's Aura AI — not financial advice
Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.
The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.
Thomson Reuters (TRI) trades at $90.67, down 5.75% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.93% net margin and 12.63% ROE, though recent earnings showed mixed results with a Q4 2025 miss. Recent developments include a joint venture with KKR for the global print business and strategic AI implementation, positioning TRI for future growth in content and technology services.
Wall Street remains optimistic with a $129.96 consensus price target (43% upside), driven by 51.85% buy ratings. Key risks include execution of AI strategy and competitive pressures. The stock offers value with reasonable valuation multiples (P/E 27.47, P/S 5.49) and consistent dividend payments, making it attractive for long-term investors despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →